07:07 AM EST, 02/07/2025 (MT Newswires) -- Eton Pharmaceuticals ( ETON ) said Friday that the US Patent and Trademark Office has granted a patent for the formulation of its ET-600 product candidate, a desmopressin oral solution being developed as potential treatment for diabetes insipidus.

The company said the patent expires in 2044 and is expected to be listed in the FDA's Orange Book once ET-600 is approved.

Eton said it has another patent application related to the ET-600 product that is currently under review.